Integrity Alliance LLC. Makes New $30,000 Investment in Codexis, Inc. $CDXS

Integrity Alliance LLC. bought a new position in Codexis, Inc. (NASDAQ:CDXS) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,070 shares of the biotechnology company’s stock, valued at approximately $30,000.

Several other large investors also recently made changes to their positions in CDXS. Nuveen LLC acquired a new stake in shares of Codexis in the first quarter valued at approximately $3,358,000. Assenagon Asset Management S.A. increased its stake in shares of Codexis by 109.2% in the first quarter. Assenagon Asset Management S.A. now owns 602,288 shares of the biotechnology company’s stock valued at $1,620,000 after purchasing an additional 314,424 shares during the period. Nuveen Asset Management LLC increased its stake in shares of Codexis by 18.6% in the fourth quarter. Nuveen Asset Management LLC now owns 1,812,345 shares of the biotechnology company’s stock valued at $8,645,000 after purchasing an additional 283,760 shares during the period. Prescott Group Capital Management L.L.C. increased its stake in shares of Codexis by 91.5% in the first quarter. Prescott Group Capital Management L.L.C. now owns 568,974 shares of the biotechnology company’s stock valued at $1,531,000 after purchasing an additional 271,800 shares during the period. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of Codexis by 24.3% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,070,253 shares of the biotechnology company’s stock valued at $2,879,000 after purchasing an additional 209,298 shares during the period. Institutional investors and hedge funds own 78.54% of the company’s stock.

Codexis Trading Down 0.4%

Codexis stock opened at $2.43 on Monday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 5.70 and a current ratio of 5.82. The firm has a market cap of $219.36 million, a price-to-earnings ratio of -2.93 and a beta of 2.54. Codexis, Inc. has a 1 year low of $1.90 and a 1 year high of $6.08. The firm’s 50 day moving average price is $2.80 and its two-hundred day moving average price is $2.57.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. The firm had revenue of $15.33 million for the quarter, compared to analyst estimates of $14.18 million. Codexis had a negative net margin of 113.67% and a negative return on equity of 105.83%. On average, research analysts predict that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Codexis from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 16th. One research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.00.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.